AMPA receptor GluRA subunits with mutations at position 750, a residue shown previously to control allosteric regulation by cyclothiazide, were analyzed for modulation of deactivation and desensitization by cyclothiazide, aniracetam, and thiocyanate. Point mutations from Ser to Asn, Ala, Asp, Gly, Gln, Met, Cys, Thr, Leu, Val, and Tyr were constructed in GluRA flip . The last four of these mutants were not functional; S 750 D was active only in the presence of cyclothiazide, and the remaining mutants exhibited altered rates of deactivation and desensitization for control responses to glutamate, and showed differential modulation by cyclothiazide and aniracetam. Results from kinetic analysis are consistent with aniracetam and cyclothiazide acting via distinct mechanisms. Our experiments demonstrate for the first time the functional importance of residue 750 in regulating intrinsic channel-gating kinetics and emphasize the biological significance of alternative splicing in the M3-M4 extracellular loop.
AMPA subtype ionotropic glutamate receptors are assembled from subunits encoded by multiple gene families that are differentially expressed in subpopulations of neurons and glia (Boulter et al., 1990; Keinänen et al., 1990; . The wide variety of functionally distinct native AMPA receptor responses recorded in CNS tissue (Burnashev et al., 1992; Jonas and Sakmann, 1992; Raman and Trussell, 1992; Livsey et al., 1993 ) is likely to result from assembly of different combinations of subunits. The results of single-cell PCR analyses provide strong support for this hypothesis (Lambolez et al., 1992; Bochet et al., 1994; Geiger et al., 1995) and suggest that the kinetics of excitatory postsynaptic currents in individual cells, which are determined by a combination of receptor deactivation, desensitization, and the rate of recovery from the desensitized state (Edmonds et al., 1995; Trussell and Otis, 1996) , must also be controlled by subunit composition.
Recent studies on memory-and cognition-enhancing drugs implicate AMPA receptors as their underlying target of action (Staubli et al., 1994a,b; Zivkovic et al., 1995) . Cognitionenhancing drugs that are thought to work by potentiating glutamatergic synaptic efficacy fall into two categories, the pyrrolidinones aniracetam, piracetam, and the related compound 1-BCP (Isaacson and Nicoll, 1991; Tang et al., 1991; Vyklicky et al., 1991; Hestrin, 1992; Gouliaev and Senning, 1994; Staubli et al., 1994b) and the benzothiadiazines cyclothiazide, diazoxide, and IDRA21 (Yamada and Rothman, 1992; Bertolino et al., 1993; Patneau et al., 1993; Yamada and Tang, 1993) . Both categories of drug slow the rate of AMPA receptor deactivation and desensitization (Isaacson and Nicoll, 1991; Vyklicky et al., 1991; Hestrin, 1992; Patneau et al., 1993; Barbour et al., 1994) . Previous work has demonstrated that for AMPA receptors an alternatively spliced exon termed the flip/flop domain , which forms part of the extracellular M3-M4 loop Stern-Bach et al., 1994; Bennett and Dingledine, 1995) , regulates the kinetics of the onset of and recovery from desensitization as well as AMPA receptor sensitivity to cyclothiazide and aniracetam Lomeli et al., 1994; Mosbacher et al., 1994; Partin et al., 1994; Johansen et al., 1995) . The findings that RNA splicing and RNA editing of this region are regulated in a cell-specific and developmentally programmed manner (Monyer et al., 1991; Lomeli et al., 1994) suggest that this region plays a critical role for AMPA receptor synaptic function.
The localization of molecular determinants of desensitization to this small (38 amino acid) region of the protein makes the flip/flop domain a good target for mutational analysis. We showed previously that exchange of a single residue at position 750 in GluRA (flip Ser and flop Asn) underlies differential modulation of desensitization by cyclothiazide for AMPA receptor splice variants (Partin et al., 1995) . The role of this residue in controlling sensitivity to other allosteric modulators of AMPA receptors has not been addressed. Also unknown is whether the effects of cyclothiazide and aniracetam on deactivation are regulated by alternative splicing. To address these issues, we constructed a series of position 750 mutations substituting amino acids with different side chain moieties. These were compared to wild-type receptors for differences in deactivation, desensitization, and modulation by cyclothiazide, aniracetam, and thiocyanate. Using both whole-cell and outside-out patch experiments by fitting the decay of the response in the continuous presence of agonist from 95% of peak to steady state with a single-exponential function ( des ); where noted we used the sum of two exponentials ( f and s ). The rate of deactivation was estimated by fitting a single exponential ( deact ) to responses to 1 msec applications of agonist. When there was substantial desensitization during the initial component of responses to 1 msec applications of agonist, the rate of deactivation was estimated from fits to the subsequent fast component of decay that developed after removal of agonist and that varied in amplitude between 90 and 20% of the peak response. In all cases, deactivation was faster than desensitization, such that there was a clear increase in rate of decay after removal of glutamate, even for responses for which there was substantial (Ͼ50%) desensitization in response to 1 msec applications of glutamate. Sensitivity to cyclothiazide, aniracetam, and thiocyanate was estimated by comparing desensitization and deactivation time constants in the absence and presence of modulator. Whole-cell responses are shown individually; patch responses are the average of 5-20 successive agonist applications. Data are presented as mean Ϯ SEM except as noted. When statistical analysis was performed, Student's unpaired one-and two-tailed t tests were used.
Kinetic modeling was performed using FastFlow, a previously described program written by Dr. John Clements . The initial rate constants used for modeling were taken from the three-binding-site model of Raman and Trussell (1995) but were modified to reproduce the properties of recombinant GluRA as determined experimentally. This entailed (1) removing the third agonist-binding step (C3) and two open states (O 2 slow and O 3 ), yielding decays that were well fit by single-rather than double-exponential functions, (2) slowing the rates of channel opening and closing by half, and (3) slowing the microscopic rates for onset of desensitization and recovery from desensitization such that the modeled responses desensitized and recovered with time constants similar to those found experimentally for recombinant GluRA. The affinity of glutamate for the desensitized agonist-bound states was adjusted to satisfy microscopic reversibility. The rates for binding of cyclothiazide and aniracetam were modeled based on experimental measurements of the affinities/efficacies of the respective modulator.
Analysis of the structure of GluRA was made using model coordinates for GluR3 provided by Dr. Patrick J. O'Hara (ZymoGenetics, Seattle, WA). The model was visualized using either QUANTA V4.0 (Molecular Simulations, Burlington, MA) or LOOK V2.0 (Molecular Applications Group, Palo Alto, CA). The predicted effects of point mutations were calculated and visualized using an algorithm of LOOK that allows point mutations at a single residue to be generated, identifies the nearest neighbors (within a 5 Å radius) of that residue, and then calculates the predicted conformation of the side chains of the selected residue and the nearest neighbors as a consequence of the mutation. The mutated structure was then overlaid with the nonmutated structure for comparison.
RESULTS

Position 750 mutations differentially regulate responses to cyclothiazide and aniracetam
To determine the constraints at position 750 that influence receptor gating and allosteric modulation by cyclothiazide and aniracetam, we mutated the Ser residue at this site in GluRA i to Asn, Ala, Asp, Gly, Gln, Met, Cys, Thr, Leu, Val, and Tyr (Fig. 1 A) . The resulting cDNAs were expressed as homo-oligomers by transient transfection of 293 cells and assayed by rapid perfusion in the whole-cell configuration. The mutants S 750 T, S 750 L, S 750 Y, and S 750 V did not generate functional responses; S 750 C and S 750 M expressed poorly; S 750 D gave responses only in the presence of cyclothiazide; and the remaining mutants generated robust responses to glutamate in both the presence and the absence of modulators. Figure 1 B shows examples of whole-cell currents evoked by 1 mM glutamate in the presence of 100 M cyclothiazide for wild-type GluRA i , GluRA o , and some of the position 750 substitutions that were found to be functional. The only receptor for which desensitization was essentially blocked was wild-type GluRA i (Table 1) ; all of the functional mutants studied continued to show desensitization in the presence of cyclothiazide. The rate of onset of desensitization was slowed most for S 750 A ( des 1690 Ϯ 149 msec; n ϭ 11). An intermediate response similar to that for wild-type GluRA o ( des 301 Ϯ 14 msec; n ϭ 9) was observed for S 750 G ( des 332 Ϯ 45 msec; n ϭ 6) and S 750 N ( des 336 Ϯ 20 msec; n ϭ 12). For S 750 M, S 750 C, and S 750 Q, the rate of onset of desensitization was rapid ( des 3-6 msec; n ϭ 2-7) and not significantly different from control (Table 1) . S 750 D was unusual in that it expressed no current under control conditions, but large currents in the presence of cyclothiazide; the decay in the presence of cyclothiazide was best fit by a double exponential [ f 58 Ϯ 5.0 msec (A f 38 Ϯ 3%); s 2857 Ϯ 328 msec; n ϭ 9]. Because of the limited solubility of cyclothiazide in physiological solutions, we were unable to examine the effects of higher concentrations on S 750 D or the other mutants.
As reported previously, aniracetam also shows splice-variant specificity for modulation of desensitization but, in contrast to cyclothiazide, the effect is greater for GluRA o than GluRA i (Johansen et al., 1995) . To determine the role of position 750 in differential modulation by aniracetam, the desensitization kinetics of the same mutants assayed for modulation by cyclothiazide were analyzed for sensitivity to 5 mM aniracetam (Fig. 2) , a concentration chosen on the basis of previous work on native AMPA receptors and which is at the solubility limit of aniracetam in physiological saline with 1% DMSO (Isaacson and Nicoll, 1991; Vyklicky et al., 1991) . As seen from the overlay of representative traces in Figure 2 B, aniracetam slowed the onset of desensitization of S 750 N ( des 31 Ϯ 3.2 msec; n ϭ 7) to a greater extent than for GluRA i ( des 20 Ϯ 1.4 msec; n ϭ 5); the extent of modulation for S 750 N was similar to that for GluRA o ( des 32 Ϯ 9 msec; n ϭ 6), suggesting that an Asn residue at position 750 underlies the higher sensitivity of flop splice variants to aniracetam (Johansen et al., 1995) . However, the equilibrium current in the presence of aniracetam for S 750 N was substantially greater (15-Ϯ 5-fold potentiation of steady-state current) than for GluRA o (2.8-Ϯ 0.6-fold) or the other mutations (5-to 10-fold range). A similar observation was made for potentiation of equilibrium currents by cyclothiazide; after a 15 sec application of glutamate in Xenopus oocytes, S 750 N equilibrium current was potentiated by cyclothiazide 2.5-fold more than either S 750 A or S 750 G (data not shown), even though in the present experiments des in the presence of cyclothiazide was much slower for S 750 A than for S 750 N or S 750 G (Table 1) . Figure 3 plots the change in time constant of onset of desensitization for mutations that were modulated by cyclothiazide and aniracetam versus increasing size of the amino acid side chain at position 750. For both drugs, one residue is clearly preferred; however, the amino acid permitting the most efficacious modulation for cyclothiazide is different than for aniracetam. For both drugs, side chains that are either larger or smaller result in less efficacious modulation. In the case of cyclothiazide, this effect is were introduced in GluRA i at position 750 and are grouped according to functional criteria. B, Whole-cell currents evoked from transiently transfected 293 cells expressing wild-type or mutant receptors. Currents were evoked by a 2 sec application of 1 mM glutamate after preincubation for Ͼ30 sec with 100 M cyclothiazide. Decays were well fit with a single exponential (superimposed on traces), with the exception of wild-type GluRA i , which desensitized too slowly to be fit, and S 750 D, which was best fit by a double exponential. Every point mutation studied altered the ability of cyclothiazide to slow the onset of desensitization, as compared to wild-type GluRA i , with S 750 M and S 750 Q permitting little and no modulation, respectively. Calibration bars represent 500 msec and 500 pA, except for S 750 M, for which the current bar represents 50 pA. extreme, and although cyclothiazide is much more efficacious than aniracetam it is only Ser 750 for which cyclothiazide essentially blocks desensitization. For aniracetam, mutants with a broader range of side chains show modulation of desensitization (compare modulation by aniracetam but not by cyclothiazide of S 750 M and S 750 Q), yet the difference in efficacy of aniracetam between the most and least sensitive mutants is less than fourfold. An interesting exception to this is S 750 D, which is strongly modulated by cyclothiazide yet insensitive to aniracetam. S 750 D also shows no control response in the absence of modulators, although when expressed in oocytes there was a small (1-2 nA) equilibrium current in response to glutamate (data not shown). The relative differences in side chain sensitivity and efficacy for modulation by aniracetam and cyclothiazide for position 750 mutants could arise through a number of mechanisms including changes in the structure of a single binding pocket that differentially affects the two drugs, or modulation via different mechanisms, one of which limits the efficacy of modulation by aniracetam but not cyclothiazide.
The mutants S 750 T, S 750 L, S 750 Y, and S 750 V generated nonfunctional receptors. This could arise from a variety of causes: gross misfolding of the protein, inappropriate intermolecular contacts such that the subunits cannot associate to form homooligomers and subsequently fail to reach the plasma membrane, or inappropriate intramolecular packing resulting in localized deformation of the helix-turn-helix motif that is thought to exist in this region of the flip/flop module (O'Hara et al., 1993; SternBach et al., 1994) . To test for appropriate folding and assembly, we performed immunofluorescence experiments, staining both live and permeabilized transfected 293 cells with anti-peptide antisera raised against the N-terminal domain of GluR1 (R. Wenthold, unpublished observations). We found that the level of immunoreactivity for the nonfunctional mutant receptors S 750 L and S 750 V and their cellular localization in the plasma membrane of live cells were indistinguishable from that for wild-type GluRA i (data not shown), suggesting that these mutant proteins were correctly folded, assembled, and inserted in the plasma membrane. In contrast, although the intracellular level of S 750 T immunoreactivity was similar to wild-type, little or no immunoreactivity could be detected on the plasma membrane of live cells.
To predict the effect of the mutations on intramolecular packing, we analyzed the predicted structure of the mutations using the LOOK modeling program (see Materials and Methods). Substitutions at position 750 were introduced into a model of GluR3 developed by O'Hara and colleagues (Stern-Bach et al., 1994) based on homology of glutamate receptors with bacterial periplasmic amino acid-binding proteins (O'Hara et al., 1993; Kuryatov et al., 1994; Stern-Bach et al., 1994) . The predicted perturbations of local structure as a consequence of mutations that disrupted modulation by cyclothiazide (S 750 Q) or resulted in a nonfunctional receptor (S 750 L) were both minimal. This suggests that position 750 mutations that result in nonfunctional receptors either disrupt contacts in the flip/flop region that are beyond the region of homology of AMPA receptor subunits with bacterial periplasmic amino acid-binding proteins or disrupt intermolecular contacts with a neighboring subunit.
Mutations at Ser 750 alter control kinetics of deactivation and desensitization
Whole-cell recordings with position 750 mutants suggest that S 750 Q desensitized slightly faster and that S 750 A desensitized slower than the other receptors tested (Table 1) . Observations of altered desensitization kinetics raised the possibility that deactivation kinetics could also differ, but the whole-cell recording technique lacks sufficient resolution for this determination. Therefore, deactivation kinetics were measured for GluRA i , GluRA o , S 750 N, S 750 Q, and S 750 A with 1 msec applications of 10 mM glutamate to outside-out patches. The subunits that were chosen for further study represent naturally occurring isoforms (GluRA i and GluRA o ), express a critical determinant of differential modulation by aniracetam and cyclothiazide (S 750 N), or exhibit altered desensitization kinetics (S 750 A and S 750 Q). Outside-out patch responses of wild-type and mutant GluRA subunits revealed rapid kinetics, with onset of desensitization even during a 1 msec application of glutamate, such that for different subunits the start of deactivation was fit well only for the later phase of the response, beginning from between 95 and 20% of the peak response. The deactivation kinetics of S 750 A ( deact 0.97 Ϯ 0.06 msec; n ϭ 21) were slower ( p Ͻ 0.01 vs GluRA i ), and those for S 750 Q ( deact 0.68 Ϯ 0.03 msec; n ϭ 17) were faster ( p Ͻ 0.05 vs GluRA i ) than other subunits tested (Fig. 4 A,B) . Similarly, S 750 A ( des 3.95 Ϯ 0.17 msec; n ϭ 22) desensitized significantly more slowly ( p Ͻ 
No response (n ϭ 12) 5.9 Ϯ 0.5 (n ϭ 7)
No response (n ϭ 6) 13 Ϯ 1.5 (n ϭ 7)
5.2 Ϯ 0.9 (n ϭ 10)
Time constants are given in msec as mean Ϯ SEM. Colquhoun et al., 1992) , are reminiscent of the fast kinetics found for AMPA receptors in nMAG neurons (Raman and Trussell, 1995) , and are only slightly slower than reported for homomeric GluRD . It had been reported that RNA editing of the Arg/Gly site in the N terminus of the flip/flop domain results in a change in the time constant ( rec ) for recovery from desensitization (Lomeli et al., 1994) . However, the intronic sequences necessary for RNA editing at this site are not found in the GluRA gene and, therefore, RNA editing of GluRA is not found in vivo. To verify that point mutations at position 750 did not affect recovery from desensitization, we measured rec for GluRA i , GluRA o , and three of the point mutations (Fig. 4 E,F ) and found that they had indistinguishable time constants for recovery from desensitization (mean rec 147 Ϯ 3 msec; n ϭ 5-8). Surprisingly, this value is substantially slower than reported previously for homo-oligomeric AMPA receptors assembled from GluRC or GluRD (Lomeli et al., 1994) . Technical reasons for this difference were eliminated by measuring rec for hetero-oligomeric AMPA receptors generated by assembly of GluRA i with GluRB i , which gave rec 71 Ϯ 5 msec (n ϭ 5), similar to previously published values (Lomeli et al., 1994) .
Cyclothiazide and aniracetam selectively modulate deactivation of AMPA receptor splice isoforms
Both cyclothiazide and aniracetam modulate deactivation of native AMPA receptors (Hestrin, 1992; Patneau et al., 1993; Barbour et al., 1994) . Because AMPA receptor splice variants show different sensitivity to these drugs, we examined whether modulation of deactivation is also sensitive to alternative splicing and whether there is a correlation between modulation of deactivation and modulation of desensitization. We looked first at the effects of cyclothiazide and aniracetam on deactivation of wild-type GluRA i and GluRA o (Fig. 5) . Cyclothiazide slowed the rate of deactivation of GluRA i by 2.40-Ϯ 0.27-fold (n ϭ 8), but did not modulate deactivation of GluRA o (n ϭ 11). Surprisingly, in view of the much weaker effects of aniracetam on desensitization, we found that deactivation for GluRA o was slowed 4.09-Ϯ 0.24-fold (n ϭ 5) by aniracetam even though cyclothiazide failed to modulate deactivation for this splice variant. For GluRA i aniracetam produced a 2.23-Ϯ 0.19-fold (n ϭ 6) slowing of deactivation similar to the effect of cyclothiazide. We concluded that both compounds differentially modulate deactivation as well as desensitization; for cyclothiazide the effects were greater for GluRA i than for GluRA o , whereas the opposite was true for aniracetam. We then examined modulation of deactivation for three of the point mutants that showed altered desensitization in the presence of cyclothiazide or aniracetam, S 750 N, S 750 A, and S 750 Q (Fig. 6) . Modulation of deactivation by cyclothiazide followed the same trend as modulation of desensitization in that clearly a Ser residue at position 750 permits the most efficacious slowing of deactivation (2.40-Ϯ 0.27-fold; n ϭ 8); deactivation of S 750 A was slowed by 1.51-Ϯ 0.11-fold (n ϭ 11), whereas deactivation of S 750 N and Time constants for deactivation were estimated from single-exponential fits starting from ϳ90 to 60% of the peak amplitude (arrows); time constants for desensitization were estimated from a single-exponential fit from 95% of peak. C, Bar plot of the time constants of deactivation (mean Ϯ SEM) as determined from 1 msec application of 10 mM glutamate. Asterisks above the bars indicate that S 750 A deactivated significantly more slowly ( p Ͻ 0.01) and S 750 Q deactivated more rapidly ( p Ͻ 0.05) than wild-type GluRA i . Values in parentheses represent the number of patches analyzed. D, Bar plot of the time constants of desensitization (mean Ϯ SEM) as determined from 20 -100 msec applications of 10 mM glutamate. Asterisks above the bars indicate that S 750 A desensitized significantly more slowly ( p Ͻ 0.001) and S 750 Q desensitized more rapidly ( p Ͻ 0.001) than GluRA i . E, Traces from a paired-pulse protocol used to determine the kinetics of recovery from desensitization for wild-type GluRA i . Shown are 12 overlaid traces, each consisting of a 10 msec conditioning pulse of 10 mM glutamate followed by test pulses at intervals of 10 -670 msec. Traces are normalized to correct for rundown (Ͻ6% in the example shown). F, The ratio of the peak amplitude of the test response to the conditioning response (I 2 /I 1 , mean Ϯ SEM) plotted versus interpulse interval for GluRA i , GluRA o , and three point mutants were well fit with an exponential function, 1 Ϫ [exp(Ϫt/ rec )], of time constant 147 msec. There was no significant difference for rec among the five receptors studied. S 750 Q was not affected (Fig. 6 B, Table 2 ). Aniracetam slowed deactivation for S 750 N (3.41-Ϯ 0.22-fold; n ϭ 9) to a greater extent than the other mutants examined, similar to its greater effect on desensitization for S 750 N versus S 750 A and S 750 Q (Fig.  3) . In general, although there was a clear correlation between the effect of these modulators on desensitization and deactivation kinetics (Fig. 6 B,C) , this is true qualitatively rather than quantitatively because for S 750 A desensitization was efficaciously modulated by cyclothiazide (145-fold slowing of the onset of desensitization), whereas deactivation was not (1.52-fold slowing). The kinetics of desensitization measured in outside-out patches were consistently faster (1.1-to 2.9-fold, depending on the subunit and modulator) than those observed by whole-cell recording (Tables  1, 2 ). The reasons for this difference are unclear, but most likely reflect slow application of agonist for whole-cell recording and possibly altered channel properties in outside-out patches (Tong and Jahr, 1994) .
Thiocyanate modulation of AMPA receptor splice isoforms
Recent experiments on native and reconstituted AMPA receptors (Bowie and Smart, 1993; Arai et al., 1995; Kessler et al., 1996) have shown that thiocyanate is a modulator of desensitization, but with the opposite effect from that produced by cyclothiazide and aniracetam, because thiocyanate increases the extent and rate of onset of desensitization. To test for differential sensitivity of AMPA receptor splice isoforms to thiocyanate, we first compared whole-cell responses to 500 M AMPA in the presence and absence of 20 mM thiocyanate (Fig. 7A ) using protocols similar to those for experiments on native receptors expressed in hippocampal slices (Arai et al., 1995) , for which the effect of thiocyanate was shown to be greater with AMPA rather than glutamate as agonist. The effect of thiocyanate on GluRA i was similar to that found for native AMPA receptors in hippocampal neurons in that the peak was reduced 17 Ϯ 3% and des accelerated from 7.2 Ϯ 0.5 to 5.1 Ϯ 0.3 msec (n ϭ 21). The results were different for GluRA o , however, in that the peak was consistently increased by 38 Ϯ 14%, and des slowed from 7.4 Ϯ 0.6 to 8.3 Ϯ 0.5 msec (n ϭ 6). We also tested S 750 Q (resistant to cyclothiazide) and S 750 N (increased sensitivity to aniracetam) for modulation of desensitization by thiocyanate (Fig. 7A ) and found that responses for S 750 N were similar to those for GluRA o , with des essentially unchanged (7.6 Ϯ 0.9 to 7.9 Ϯ 1.0 msec; n ϭ 15) but with the peak amplitude potentiated (44 Ϯ 6%), whereas for S 750 Q des accelerated from 6.1 Ϯ 0.6 to 4.4 Ϯ 0.5 msec (n ϭ 12) without a significant change in the amplitude of the current (98 Ϯ 14%). Although S 750 A desensitized almost twice as slowly ( des 11.4 Ϯ 1.3; n ϭ 13) as S 750 Q (6.1 Ϯ 0.6 msec; n ϭ 12), thiocyanate accelerated the rate of onset of desensitization (ϳ33%) to a similar extent for both mutants (Fig. 7A, Table 1 ).
To better resolve modulation of desensitization by thiocyanate, as well as to determine whether thiocyanate modulates deactivation for wild-type GluRA i and GluRA o , we tested the effects in outside-out patches of 20 mM thiocyanate on responses evoked by 4 receptors. Note that there are three y-axes: one for control responses to 10 mM glutamate; one for desensitization in the presence of cyclothiazide; and one for desensitization in the presence of aniracetam. Asterisk denotes that, for GluRA i , the value represents the time constant of dissociation of cyclothiazide (15.7 Ϯ 0.7 sec) estimated from experiments shown in Figure  8 D. Plus signs (ϩ) denote values that include the weighted averages of data fit with two exponentials (see Table 2 ). Arrows denote the start of single-exponential fits for analysis of deactivation. Cyclothiazide slowed deactivation for S 750 A, but not for S 750 N or S 750 Q. Responses to 1 msec applications of 10 mM glutamate in the absence or presence of 5 mM aniracetam revealed that modulation of deactivation was most efficacious for S 750 N but also occurred for S 750 Q for which cyclothiazide was inactive. B, Bar plots of the time constants for deactivation ( deact , mean Ϯ SEM) as determined for controls (open bars), in the presence of 100 M cyclothiazide (solid bars), or in the presence of 5 mM aniracetam (hatched bars) for GluRA i , GluRA o , and the three point mutants examined in the outside-out patch configuration. C, Bar plots of time constants for desensitization ( des , mean Ϯ SEM) for the same 10 mM glutamate, which was chosen to allow comparison with the effects of other modulators in outside-out patches (Fig. 7B ). We found a 1.6-fold slowing of deact for GluRA o from 0.69 Ϯ 0.05 to 1.12 Ϯ 0.08 msec (n ϭ 8, p Ͼ 0.0001), whereas for GluRA i deact was not significantly changed (0.65 Ϯ 0.04 to 0.73 Ϯ 0.04 msec; n ϭ 8). Thiocyanate had a differential effect on desensitization, accelerating des for GluRA i (2.17 Ϯ 0.11 to 1.58 Ϯ 0.09 msec), but slowing des for GluRA o (from 3.21 Ϯ 0.27 to 3.77 Ϯ 0.29 msec). Therefore, modulation of deactivation and desensitization by thiocyanate is distinct from modulation by cyclothiazide and aniracetam, but is sensitive to amino acid changes in the flip/flop domain and, specifically, to changes at position 750.
Kinetic modeling of differential modulation by aniracetam and cyclothiazide
A variety of kinetic models for ligand-gated ion channels have been developed to describe activation, deactivation, and desensitization. Figure 8A presents a kinetic model for AMPA receptor modulation by aniracetam and cyclothiazide, derived primarily from the work of Vyklicky et al. (1991) , Raman and Trussell (1995) , and Kessler et al. (1996) . The rate constants for the model are given in Table 3 (see also Materials and Methods). The model describes binding of two molecules of agonist leading to a conformational transition to a single open state. In the continued presence of agonist, there is a high probability that the receptor will undergo further transitions to nonconducting, agonist-bound desensitized states (R d A and R d A 2 ). After channel opening by brief pulses of agonist, a significant fraction of receptors return to the unliganded state without entering the desensitized states R d A and R d A 2 . The model assumes binding of one molecule of modulator and does not address whether aniracetam and cyclothiazide bind to the same site. The model allows desensitization to occur only through closed states, although this assumption has not been proven. Although these simplifications facilitate analysis of modulation, native AMPA receptors are known to have subconductance states (Howe et al., 1991) and, in addition, as modeled by Raman and Trussell (1995) , there is evidence for multiple and kinetically distinct open states. Figure 8 B shows simulated responses to 10 mM glutamate generated by the models developed here. These are similar in many ways to experimental responses for GluRA (Figs. 4, 5): there is marked desensitization with a 1 msec pulse of agonist; deact (0.85 msec) is 3.6-fold faster than des (3.1 msec); responses to prolonged application of glutamate desensitize to Ͻ1% of peak.
Modulation by aniracetam similar to that observed for GluRA o was achieved by slowing the closing rate constant sixfold. This reproduced slowing of deactivation ( deact 5.0 msec) and desensitization ( des 16.6 msec); for GluRA o the experimentally recorded mean time constants were 3.31 and 26 msec, respectively. As would be expected from a cyclic model, slowing the closing rate constant changes accessibility to ligand-bound desensitized states, which results in a slowing of the rate of onset of desensitization (Vyklicky et al., 1991) . A similar stabilization of the open state could occur alternatively if modulation by aniracetam resulted from an accelerated rate of channel opening. A kinetic model increasing the opening rate constant 30-fold did slow deactivation ( deact 3.4 msec), but it also slowed desensitization ( des 95 msec) to a much greater extent than observed experimentally, leading us to conclude that modulation of the channel closing rate rather than channel opening was a more probable explanation for the effects of aniracetam. In the model developed here, the channel opening rate constant, 30,000 sec Ϫ1 in the absence of modulators, would have to be changed to 900,000 sec Ϫ1 to slow deactivation to the extent seen experimentally. This high rate seems improbable and, indeed, is substantially faster than the maximum opening rate estimated for nicotinic (12,000 sec
Ϫ1
; Liu and Dilger, 1991) and GABA A (3500 sec
; Jones and Westbrook, 1995) receptor channels. Additional evidence consistent with modulation of the closing rate constant by aniracetam comes from single-channel studies on native receptors for which modulation by aniracetam is observed as an increased mean open time and burst length (Vyklicky et al., 1991) . A final prediction of our model is a linear relationship between modulation of deactivation and modulation of desensitization by aniracetam, a correlation confirmed experimentally (see Discussion; Fig. 9) .
A kinetic scheme reproducing modulation by cyclothiazide for GluRA i is shown in Figure 8 A (right), but in this case modulation occurs through "stabilization" of an agonist-bound nondesensitized closed state (RMA 2 ). This is achieved by increasing agonist affinity for the RMA 2 state 20-fold and slowing the rate of onset of desensitization from the RMA 2 state 10,000-fold. Modulation of the onset of desensitization would not account for the slowing of deactivation that is seen experimentally, whereas increasing agonist affinity slows the rate of deactivation by slowing agonist dissociation, but only when the rate of entry into desensitized states is reduced. The model predicts very efficacious modulation of desensitization with weaker modulation of deactivation, an effect observed experimentally for cyclothiazide modulation of all GluRA constructs studied. The model also predicts that, different Open tip junction potentials are shown above the current traces. Deactivation was essentially unchanged for GluRA i but slowed for GluRA o in the presence of thiocyanate. The onset of desensitization of GluRA i was faster in the presence of thiocyanate, whereas thiocyanate slowed the onset of desensitization for GluRA o , similar to whole-cell responses recorded using AMPA as agonist. The data were fit with a single exponential, rec ϭ 125 msec, similar to experimental values. D, Decays of a simulated response (thin trace) and an experimentally recorded response of GluRA i to 1 mM glutamate in the absence of modulator after preincubation with 100 M cyclothiazide. The rate of decay is assumed to reflect the unbinding of cyclothiazide. For GluRA i the mean dissociation rate was 15.7 Ϯ 0.7 sec; for the simulation it was 11.3 sec.
from modulation by aniracetam, there should not be a linear correlation between modulation of deactivation and desensitization by cyclothiazide. The simulated data traces reproduce these features, with deact (4.8 msec) slowed only 5.6-fold but desensitization essentially abolished. This is similar to data collected for GluRAi ( deact 2.1 msec, 2.4-fold slower than control) but with Ͻ6% desensitization within 100 msec. Figure 8C shows that for the models developed the kinetics of recovery from the desensitized state are slow ( rec 125 msec) with kinetics similar to those recorded experimentally for GluRA ( rec 147 msec; Fig. 4 E) . Because GluRA i desensitizes very little in the presence of cyclothiazide, it is difficult to assign a value for the "rate of onset of desensitization" as a measure of the efficacy of cyclothiazide. We therefore performed experiments to measure the dissociation rate of cyclothiazide in the presence of glutamate for GluRA i ( off 15.7 Ϯ 0.7 sec) and for the model ( off 11.3 sec; Fig. 8 D) and found the rates of dissociation to be similar. Simulated doseresponse relationships with 1 mM glutamate as agonist yielded an EC 50 for cyclothiazide of 1.0 M and a shift in the EC 50 of the glutamate peak response from 936 to 26 M in the presence of 100 M cyclothiazide. This substantially reproduces the results of Yamada and Tang (1993) , for which the cyclothiazide EC 50 was 12 M with quisqualate as agonist, and the EC 50 of the quisqualate peak response was shifted from 280 to 3 M in the presence of 10 M cyclothiazide. The apparent stabilization of RMA 2 as the underlying mechanism of modulation by cyclothiazide has been discussed previously for native AMPA receptors (Patneau et al., 1993; Kessler et al., 1996) . It is supported by work demonstrating that there is no change in single-channel conductance in the presence of cyclothiazide (Yamada and Tang, 1993) , by data that show a decrease in [ 3 H]AMPA binding in the presence of cyclothiazide attributable to the higher affinity of AMPA for the desensitized state (Hall et al., 1993) , and by the finding that cyclothiazide causes a leftward shift of kainate dose-response curves (Patneau et al., 1993; Partin et al., 1994) . However, it is not possible with the present experiments to distinguish whether this occurs through a cyclothiazide-induced destabilization of the desensitized state, stabilization of the closed nondesensitized state (RMA 2 ), or a combination of both.
DISCUSSION
We report here a detailed analysis of a critical site in the alternatively spliced flip/flop domain of AMPA receptors (position 750 in GluRA) that affects intrinsic channel gating kinetics and the ability of three different compounds to modulate both desensitization and deactivation. These effects could reflect (1) coupling of deactivation and desensitization, (2) that structural determinants directing these conformational transitions share a set of amino acids (some of which are encoded within the flip/flop domain), and/or (3) that the modulators bind at or near this site. In the next section, we discuss our interpretation of the functional contributions of the flip/flop domain to AMPA receptor properties.
In the kinetic model presented in Figure 8 , slowing the closing rate constant results in a concomitant slowing of the macroscopic rate of onset of desensitization (Vyklicky et al., 1991) . As recently noted by Trussell and Otis (1996) , experimental observations on AMPA receptors in different neuronal populations show a similar covariance between the time constants of deactivation and desensitization. Further support for this is shown in Figure 9A , which combines data from our study with published values for a large number of neuronal and recombinant AMPA receptors. Of the position 750 point mutations studied in detail, S 750 Q and S 750 A varied from GluRA i in both des and deact , whereas for S 750 N neither process was altered (Fig. 9B ). This suggests that determinants at position 750 can directly influence the kinetics of deactivation, resulting in a secondary effect on the kinetics of desensitization. Although for native receptors heterogeneity in the rate of onset of desensitization would be expected to result from heterogeneity in the closing rate constant, the two kinetic processes do vary independently to some extent, perhaps according to subunit composition and assembly (Geiger et al., 1995) . Evidence for variation in the rate of onset of desensitization, independent from the closing rate, is presented in Figure 9B . Wild-type GluRA i and GluRA o , both of which have a deact of 0.8 msec, (Table 2) . A more dramatic difference was reported for GluRD i and GluRD o , for which deact is similar (0.6 msec), but for which des differs fourfold between splice isoforms .
To understand further the role of individual amino acids within the flip/flop region in directing conformational transitions underlying deactivation and desensitization, it would be instructive to know with what residues Ser 750 interacts. This is made difficult because the structural model based on bacterial amino acid-binding proteins is incomplete in this region. The downstream region has been modeled to fold back toward the 750 position (Stern-Bach et al., 1994) , such that critical residues at the C terminus of the exon (KDSG/GGGD) may directly interact with position 750 to form a tertiary domain. Altered desensitization and deactivation kinetics may reflect changes in hydrogen bond interactions between the 750 position and the downstream region. For the two mutations that alter deactivation and desensitization kinetics in the opposite direction, Gln (larger than Ser) increases the rates whereas Ala (slightly smaller than Ser and aliphatic rather than hydrophilic) decreases the rates. Thus, Gln could permit a tighter interaction, whereas Ala could permit a weaker interaction, and these differences in packing might affect the conformational transitions underlying deactivation and desensitization. S 750 D, the mutant for which no control response could be recorded, might reflect stabilization of a desensitized state attributable to a strong electrostatic interaction with the downstream region (KDSG in GluRA i ). Our data suggest that within the flip/flop domain are determinants that can affect the rate of onset of desensitization via two mechanisms: (1) indirectly, by altering the rate of deactivation, as was seen with some of the 750 mutants; or (2) directly, by stabilizing the desensitized or nondesensitized conformation of the receptor.
How, then, might modulation of AMPA receptors occur? FigFigure 9 . Deactivation and desensitization are linked processes. A, Correlation between the time constants for deactivation and desensitization combining previously published values for native and recombinant AMPA receptors (q) with data from the present study (E). HMC, Hilar mossy cells; CA3, hippocampal CA3 pyramidal cells; Cx-pyramidal, neocortical layer V pyramidal cells; Cx-interneuron, neocortical layer IV nonpyramidal cells; DG-basket, dentate gyrus basket cells; MNTB, medial nucleus of the trapezoid body (auditory nucleus). Values are taken from Geiger et al. (1995) , except for nMAG (chick nucleus magnocellularis), which was taken from Raman and Trussell (1995) and recombinant GluRA i , -A o , -D i , and -D o (Lomeli et al., 1994) . Data from the present study include GluRA i , S 750 A, S 750 N, and S 750 Q. Note that the time constants for outside-out patches presented in this study were obtained using 10 mM glutamate, whereas most previous studies used 1 mM glutamate. A linear fit through the data yields a slope of 5.3 (r ϭ 0.96). A similar finding was reported recently by Trussell and Otis (1996) . The asterisk indicates that data for GluRD are taken from Mosbacher et al. (1994) . C, Comparison of the linear relationship between deact and des after making incremental changes in the closing rate constant for simulated data (solid line), and between deact and des in the presence of aniracetam (q) or cyclothiazide (Ⅺ) for mutations described in this study. The data for aniracetam lie along the line, consistent with the hypothesis that aniracetam acts via slowing the closing rate constant. D, Schematic representation of AMPA receptor domains (O'Hara et al., 1993; Stern-Bach et al., 1994; Kuryatov et al., 1994) . The N-terminal domain shares homology with LIVBP (bacterial periplasmic LeucineIsoleucine-Valine-Binding Protein; hatched region). The agonist-binding pocket is formed by two lobes (derived from N-terminal residues and residues from the M3-M4 extracellular loop) sharing homology with LAOBP (Lysine-Arginine-Ornithine-Binding Protein; gray stippled region); S1/S2 refers to the chimeric constructs (Stern-Bach et al., 1994; Kuusinen et al., 1995) , confirming that this forms the agonist-binding pocket. Putative membrane domains shown in black are embedded within the lipid bilayer Bennett and Dingledine, 1995) . The cytoplasmic domain is shown with wavy hatching; P represents the site for phosphorylation by CaM-kinase II (McGlade-McCulloh et al., 1993; Yakel et al., 1995) . The flip/flop region is shown as a helix-turn-helix motif that connects the agonist-binding region to M4. ure 9C plots the relationship of des and deact from the kinetic model presented in Figure 8 , showing linear variation of des and deact , with a twofold slowing of the closing rate constant resulting in a fourfold slowing of des . Also plotted are experimental values for modulation of deactivation and desensitization by aniracetam and cyclothiazide for the mutations studied in this paper ( Table  2 ). The data points for aniracetam tend to lie along the line predicted for changing the closing rate constant (r ϭ 0.81), whereas the data points for cyclothiazide modulation do not. Our interpretation is that the mutants bind aniracetam with different affinities, which results in different efficacies for modulation but via a common mechanism: slowing the closing rate constant. With our kinetic model, modulation of deactivation and desensitization becomes less efficacious, with a range similar to that observed for the point mutants analyzed, as the K d for aniracetam is decreased 10-to 100-fold (data not shown). Direct measurement of the binding constants of [ 3 H] aniracetam for the mutations would be a conclusive test of this, but binding experiments with radiolabeled aniracetam are confounded by both low-affinity binding and high nonspecific binding such that effects of the point mutations would be unlikely to be resolved (Fallarino et al., 1995) . The data for cyclothiazide do not fall on the line describing a concomitant variation of desensitization and deactivation that results from slowing the closing rate constant (Fig. 9C) . Rather, we find that there is a nonlinear correlation between modulation of deactivation and desensitization by cyclothiazide that could be explained if cyclothiazide acts by stabilizing the nondesensitized closed state, which changes apparent agonist affinity, availability to the open state, and entry into the desensitized state. Aniracetam does not modulate desensitization directly and, therefore, would not modulate S 750 D, the mutation thought to stabilize the desensitized state, whereas cyclothiazide should, consistent with our experimental findings. The simplest interpretation of the experiments reported here is that cyclothiazide, aniracetam, and thiocyanate bind at or near the flip/flop region but that the determinants of binding and mechanisms of modulation are different, as seen by the results of the mutational analysis of position 750 (Figs. 3, 6 ; Table 1 ). The positive allosteric site to which cyclothiazide and aniracetam bind is different from, but may be close to, a negative allosteric site that binds GYKI 53655 (Johansen et al., 1995; Partin and Mayer, 1996; Rammes et al., 1996; Yamada and Turetsky, 1996) . Thiocyanate has an allosteric effect on the transition between the closed and the desensitized states (Kessler et al., 1996) , and we show here that this effect can be positive or negative depending on the residue at position 750.
Deactivation and desensitization are two mechanisms by which glutamate receptors terminate the flow of ions through the channel. Both processes entail transduction of an allosteric signal from the agonist-binding pocket to the pore. The flip/flop domain resides just before M4 (Fig. 9D) , and our data suggest that this region is either a necessary component of or tightly coupled to signal transduction between the agonist-binding pocket and the pore, because amino acid substitutions in this region affect both deactivation and desensitization. Bacterial periplasmic amino acid-binding proteins have been used with great success as templates for structural homology modeling of glutamate receptors yet, unlike ion channels, they do not encode their own membrane domains and, instead, associate with membrane proteins mediating amino acid transport (Ames, 1986) . The structural homology between LAOBP and GluR3, for example, ends with the helixturn-helix motif within the flip/flop domain (Fig. 1) and does not extend to the downstream set of four amino acids (KDSG/ GGGD) at the C terminus of the alternative exon (Stern-Bach et al., 1994) . One explanation for this divergence could be adaptation of the amino acids encoded in the flip/flop region to a new function, signal transduction to the pore. Binding of modulators would impede transduction of the signal, either by stabilizing one conformation or by destabilizing another. In this hypothesis, the signal from the flip/flop domain to the pore could be mediated via M4, possibly through a re-alignment of M1-M4 contacts, as has been postulated for acetylcholine receptors (Unwin, 1993) . Molecular modeling experiments have suggested that there may be a Cys bridge between residues 714 and 769 (Sutcliffe et al., 1996) , which could be the means by which the flip/flop domain is anchored with respect to the agonist-binding domain.
The kinetics of deactivation and desensitization of homooligomeric GluRA i and GluRA o and other homo-oligomeric receptors are faster than the kinetics observed in hippocampal neurons (Vyklicky et al., 1991; Colquhoun et al., 1992; Patneau et al., 1993; Fleck et al., 1996) and are somewhat similar to the kinetics reported for the chick nMAG neurons (Raman and Trussell, 1992) , rat MNTB relay neurons, and Bergmann glia (Geiger et al., 1995) . We found that for GluRA receptors the sojourn through the open, closed, and desensitized states could occur within 1 msec when activated by glutamate, which is consistent with the utilization of a fast open state described by Raman and Trussell (1995) . However, the responses from GluRA were very much slower to recover from desensitization, with rec of 147 msec versus 16 msec found in nMAG neurons. The differences between the kinetics of recombinant homo-oligomers and native receptors must be attributable to altered properties when subunits hetero-oligomerize, particularly when the complex includes GluRB or GluRD (Lomeli et al., 1994) . One remarkable feature of GluRA is the extent to which the desensitization properties of homomeric GluRA i and GluRA o differ from hetero-oligomeric complexes of GluRA i B i and GluRA o B o Lomeli et al., 1994; Partin et al., 1994) . The similarities and differences between native and recombinant receptors emphasize the concept that functional heterogeneity of glutamatergic synapses is directed by heterogeneity in subunit composition and assembly and by differential RNA splicing/editing of individual subunits. The experiments described here confirm the functional importance of the flip/flop domain in regulating intrinsic channel kinetics as well as modulation of desensitization and deactivation, and emphasize the significance of alternative splicing as a means of expanding the diverse repertoire of AMPA receptor-mediated synaptic responses.
